{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:38:32Z","timestamp":1774489112977,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2022.100676","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:44:15Z","timestamp":1671749055000},"page":"100676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0816","authenticated-orcid":false,"given":"M.P.","family":"Kicken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.D.","family":"Kilinc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Cramer-van der Welle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Houterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.E.E.M.","family":"van den Borne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.W.","family":"van de Garde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100676_bib0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100676_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","article-title":"Clinical pharmacokinetics and dose optimisation of carboplatin","volume":"33","author":"Duffull","year":"1997","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100676_bib0003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-002-0490-y","article-title":"Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support","volume":"50","author":"Shen","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0004","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-008-0856-x","article-title":"Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?","volume":"64","author":"Ekhart","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100676_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF00685696","article-title":"Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients","volume":"28","author":"Sorensen","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100676_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","article-title":"Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer","volume":"10","author":"Jodrell","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2022.100676_bib0007","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2022.100676_bib0008","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jnci\/87.8.573","article-title":"Prediction of carboplatin clearance from standard morphological and biological patient characteristics","volume":"87","author":"Chatelut","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100676_bib0009","first-page":"1693","article-title":"Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function","volume":"44","author":"Harland","year":"1984","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100676_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2146\/ajhp080200","article-title":"Estimation of creatinine clearance in morbidly obese patients","volume":"66","author":"Demirovic","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.metabol.2005.07.014","article-title":"Cockcroft-Gault formula is biased by body weight in diabetic patients with renal impairment","volume":"55","author":"Rigalleau","year":"2006","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.ctarc.2022.100676_bib0012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/j.1875-9114.2012.01098.x","article-title":"Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation","volume":"32","author":"Winter","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100676_bib0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00280-005-0012-9","article-title":"Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia","volume":"57","author":"Herrington","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.ctarc.2022.100676_bib0014","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00228-016-2080-7","article-title":"Hematological toxicity of carboplatin for gynecological cancer according to body mass index","volume":"72","author":"Gutierrez","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100676_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/07357907.2013.784778","article-title":"Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy","volume":"31","author":"Kashiwabara","year":"2013","journal-title":"Cancer Invest."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100676_bib0016","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1248\/bpb.b19-00916","article-title":"Effect of obesity on hematotoxicity induced by carboplatin and paclitaxel combination therapy in patients with gynecological cancer","volume":"43","author":"Ando","year":"2020","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00280-017-3326-5","article-title":"Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity","volume":"80","author":"Bretagne","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100676_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01100-2018","article-title":"Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer","volume":"52","author":"Cramer-van der Welle","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ctarc.2022.100676_bib0019","unstructured":"Santeon. Accessed 16-03-2021. https:\/\/santeon.nl\/; 2021."},{"issue":"13","key":"10.1016\/j.ctarc.2022.100676_bib0020","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100676_bib0021","unstructured":"National Cancer Institute (NCI). Common terminology criteria for adverse events (CTCAE). CTCAE version 4.0."},{"key":"10.1016\/j.ctarc.2022.100676_bib0022","unstructured":"Lilenbaum RC, West HJ VS. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer. UpToDate(R)."},{"key":"10.1016\/j.ctarc.2022.100676_bib0023","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/CLEP.S17191","article-title":"Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program","volume":"3","author":"Cetin","year":"2011","journal-title":"Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","article-title":"Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes","volume":"47","author":"Le Chevalier","year":"2005","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100676_bib0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/annonc\/mdp352","article-title":"A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer","volume":"21","author":"Treat","year":"2010","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100676_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037229","article-title":"Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.ctarc.2022.100676_bib0027","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2022.100676_bib0028","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100676_bib0029","unstructured":"MJ Deenen, H Kemming, K Beunen, JJ van den Hudding, C Bethlehem, T van Voorthuizen, HJM Smit, M Filius. Association between high body mass index and carboplatin-induced toxicity and hospitalization - an observational clinical cohort study. Submitted."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100676_bib0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1188\/17.ONF.E203-E212","article-title":"Predictors of unplanned hospitalizations in patients with nonmetastatic lung cancer during chemotherapy","volume":"44","author":"Fessele","year":"2017","journal-title":"Oncol. Nurs. Forum"},{"issue":"9","key":"10.1016\/j.ctarc.2022.100676_bib36","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2019.05.031","article-title":"Body mass index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: a pooled analysis of the international lung cancer consortium","volume":"14","author":"Shepshelovich","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008933","article-title":"The average body surface area of adult cancer patients in the UK: a multicentre retrospective study","volume":"5","author":"Sacco","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0033","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2014.01.030","article-title":"Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian ovarian cancer study (AOCS)","volume":"133","author":"Au-Yeung","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100676_bib0034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100676_bib0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2015.1796","article-title":"Impact of chemotherapy dosing on ovarian cancer survival according to body mass index","volume":"1","author":"Bandera","year":"2015","journal-title":"JAMA Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:33:47Z","timestamp":1762842827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222001678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":36,"alternative-id":["S2468294222001678"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100676","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100676"}}